Dr. Reddy’s Laboratories Limited (NYSE:RDY) Shares Acquired by Ballentine Partners LLC

Ballentine Partners LLC increased its holdings in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 577.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 104,715 shares of the company’s stock after acquiring an additional 89,263 shares during the quarter. Ballentine Partners LLC’s holdings in Dr. Reddy’s Laboratories were worth $1,653,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. World Investment Advisors LLC acquired a new position in Dr. Reddy’s Laboratories during the third quarter worth about $3,459,000. Nordea Investment Management AB boosted its position in Dr. Reddy’s Laboratories by 441.8% during the fourth quarter. Nordea Investment Management AB now owns 125,363 shares of the company’s stock worth $1,992,000 after acquiring an additional 102,226 shares during the last quarter. GAMMA Investing LLC boosted its position in Dr. Reddy’s Laboratories by 369.9% during the fourth quarter. GAMMA Investing LLC now owns 6,799 shares of the company’s stock worth $107,000 after acquiring an additional 5,352 shares during the last quarter. Geode Capital Management LLC boosted its position in Dr. Reddy’s Laboratories by 109.3% during the third quarter. Geode Capital Management LLC now owns 13,254 shares of the company’s stock worth $1,053,000 after acquiring an additional 6,920 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Dr. Reddy’s Laboratories by 12.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company’s stock worth $76,455,000 after acquiring an additional 114,294 shares during the last quarter. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on RDY shares. Barclays reduced their target price on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Finally, Nomura downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th.

Dr. Reddy’s Laboratories Price Performance

Shares of RDY stock opened at $14.81 on Wednesday. The firm’s 50-day moving average is $14.86 and its two-hundred day moving average is $15.54. The company has a market capitalization of $12.36 billion, a PE ratio of 23.65 and a beta of 0.51. Dr. Reddy’s Laboratories Limited has a 12 month low of $13.47 and a 12 month high of $16.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.36.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.